190 related articles for article (PubMed ID: 24562647)
21. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
[TBL] [Abstract][Full Text] [Related]
22. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A
J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414
[TBL] [Abstract][Full Text] [Related]
23. A Ukrainian multicenter prospective study of the value of PET/ CT prognostic role in primary patients with Hodgkins lymphoma in a real-life cohort.
Novosad O; Skrypets T; Pastushenko I; Kadnikova T; Gorbach O; Kozlov V; Mykhalska L; Kosinova V; Kostiukova N; Karnabeda O; Stratienko V; Novikov M; Oliinichenko O; Kmetyuk I; Karpova O; Ashykhmin A; Lukjanec O; Kriachok I
Klin Onkol; 2020; 33(6):450-457. PubMed ID: 33685195
[TBL] [Abstract][Full Text] [Related]
24. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.
Barrington SF; Kirkwood AA; Franceschetto A; Fulham MJ; Roberts TH; Almquist H; Brun E; Hjorthaug K; Viney ZN; Pike LC; Federico M; Luminari S; Radford J; Trotman J; Fosså A; Berkahn L; Molin D; D'Amore F; Sinclair DA; Smith P; O'Doherty MJ; Stevens L; Johnson PW
Blood; 2016 Mar; 127(12):1531-8. PubMed ID: 26747247
[TBL] [Abstract][Full Text] [Related]
25. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma.
Al-Ibraheem A; Anwer F; Juweid ME; Shagera QA; Khalaf AN; Obeidat S; Mansour A; Ma'koseh M; Halahleh K; Jaradat I; Almasri N; Mansour A
Sci Rep; 2022 Oct; 12(1):17702. PubMed ID: 36271128
[TBL] [Abstract][Full Text] [Related]
26. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
27. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A
Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615
[TBL] [Abstract][Full Text] [Related]
28. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.
Pavlovsky A; Fernandez I; Kurgansky N; Prates V; Zoppegno L; Negri P; Milone G; Cerutti I; Zabaljauregui S; Mariano R; Grecco HF; Basquiera AL; Saba S; Rudoy S; Sackmann F; Castano V; Remaggi G; Cabrejo M; Roveri E; Casale MF; Cabane V; Taus R; Venturini C; Sakamoto F; Varela AI; Riddick M; Pavlovsky S;
Br J Haematol; 2019 Jun; 185(5):865-873. PubMed ID: 30864146
[TBL] [Abstract][Full Text] [Related]
29. Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).
LaCasce AS; Dockter T; Ruppert AS; Kostakoglu L; Schöder H; Hsi E; Bogart J; Cheson B; Wagner-Johnston N; Abramson J; Blum K; Leonard JP; Bartlett NL
J Clin Oncol; 2023 Feb; 41(5):1023-1034. PubMed ID: 36269899
[TBL] [Abstract][Full Text] [Related]
30. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.
Rossi C; André M; Dupuis J; Morschhauser F; Joly B; Lazarovici J; Ghesquières H; Stamatoullas A; Nicolas-Virelizier E; Feugier P; Gac AC; Moatti H; Fornecker LM; Deau B; Joubert C; Fortpied C; Raemaekers J; Federico M; Kanoun S; Meignan M; Traverse-Glehen A; Cottereau AS; Casasnova RO
Haematologica; 2022 Dec; 107(12):2897-2904. PubMed ID: 35638548
[TBL] [Abstract][Full Text] [Related]
31. Can We Predict Bleomycin Toxicity with PET-CT?
Beyhan Sagmen S; Comert S; Turan Erkek E; Küçüköz Uzun A; Doğan C; Yılmaz G; Kıral N; Fidan A; Yılmaz Haksal Ç; Torun Parmaksız E
Acta Haematol; 2019; 142(3):171-175. PubMed ID: 31454795
[TBL] [Abstract][Full Text] [Related]
32. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
33. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.
Hartridge-Lambert SK; Schöder H; Lim RC; Maragulia JC; Portlock CS
Cancer; 2013 Mar; 119(6):1203-9. PubMed ID: 23132361
[TBL] [Abstract][Full Text] [Related]
34. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
[TBL] [Abstract][Full Text] [Related]
35. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.
Zinzani PL; Rigacci L; Stefoni V; Broccoli A; Puccini B; Castagnoli A; Vaggelli L; Zanoni L; Argnani L; Baccarani M; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):4-12. PubMed ID: 21894546
[TBL] [Abstract][Full Text] [Related]
36. Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
Casasnovas RO; Bouabdallah R; Brice P; Lazarovici J; Ghesquieres H; Stamatoullas A; Dupuis J; Gac AC; Gastinne T; Joly B; Bouabdallah K; Nicolas-Virelizier E; Feugier P; Morschhauser F; Sibon D; Bonnet C; Berriolo-Riedinger A; Edeline V; Parrens M; Damotte D; Coso D; André M; Meignan M; Rossi C
J Clin Oncol; 2022 Apr; 40(10):1091-1101. PubMed ID: 34990281
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A
Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.
Le Roux PY; Gastinne T; Le Gouill S; Nowak E; Bodet-Milin C; Querellou S; Mahe B; Dubruille V; Blin N; Salaun PY; Bodere-Kraeber F
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1064-71. PubMed ID: 21308370
[TBL] [Abstract][Full Text] [Related]
39. Unusual presentation of sarcoid-like reaction on bone marrow level associated with mediastinal lymphadenopathy on (18)F-FDG-PET/CT resembling an early recurrence of Hodgkin's Lymphoma.
Fallanca F; Picchio M; Crivellaro C; Mapelli P; Samanes Gajate AM; Sabattini E; Gianolli L; Messa C
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):207-9. PubMed ID: 22980128
[TBL] [Abstract][Full Text] [Related]
40. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.
Zaucha JM; Malkowski B; Chauvie S; Subocz E; Tajer J; Kulikowski W; Fijolek-Warszewska A; Biggi A; Fallanca F; Kobylecka M; Dziuk M; Woszczyk D; Rybka J; Kroll-Balcerzak R; Bergesio F; Romanowicz A; Chamier-Cieminska A; Kurczab P; Giza A; Lesniewski-Kmak K; Zaucha R; Swietlik D; Wróbel T; Knopinska-Posluszny W; Walewski J; Gallamini A
Ann Oncol; 2017 Dec; 28(12):3051-3057. PubMed ID: 28950332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
